New schizophrenia drug aims to calm severe symptoms in hospitalized patients

NCT ID NCT07105098

Recruiting now Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a new drug called NBI-1117568 can improve schizophrenia symptoms like hallucinations and disorganized thinking. About 284 adults with schizophrenia who need hospital care will receive either the drug or a placebo for 5 weeks. The study measures symptom changes using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBI-1117568
What this could lead to: If successful, this could provide a new treatment option for managing schizophrenia symptoms, potentially reducing hospital stays.
What could go wrong: This is an early Phase 3 trial with only 284 participants. The drug may not work better than placebo, and side effects are unknown. Results may not apply to all schizophrenia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neurocrine Clinical Site
RECRUITING

Culver City, California, 90230, United States
Neurocrine Clinical Site
RECRUITING

Garden Grove, California, 92845, United States
Neurocrine Clinical Site
RECRUITING

Riverside, California, 92506, United States
Neurocrine Clinical Site
RECRUITING

Atlanta, Georgia, 30328, United States
Neurocrine Clinical Site
RECRUITING

North Canton, Ohio, 44720, United States
Neurocrine Clinical Site
RECRUITING

Sliven, 8800, Bulgaria
Neurocrine Clinical Site
WITHDRAWN

Veliko Tarnovo, 5047, Bulgaria
Neurocrine Clinical Site
RECRUITING

Vratsa, 3001, Bulgaria
Neurocrine Clinical Site
RECRUITING

Győr, 9024, Hungary
Neurocrine Clinical Site
RECRUITING

Brasov, 500123, Romania
Neurocrine Clinical Site
RECRUITING

Brasov, 507190, Romania
Neurocrine Clinical Site
RECRUITING

Bucharest, 41914, Romania
Neurocrine Clinical Site
RECRUITING

Belgrade, 11000, Serbia
Neurocrine Clinical Site
RECRUITING

Gornja Toponica, 18202, Serbia
Neurocrine Clinical Site
RECRUITING

Kragujevac, 34000, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.